Northwest Biotherapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-55.7M | $-55.7M | — | $127.0K |
| FY2017 | $-36.5M | $-36.5M | — | $842.0K |
| FY2018 | $-34.6M | $-34.6M | — | — |
| FY2019 | $-31.9M | $-32.0M | $171.0K | — |
| FY2020 | $-32.1M | $-32.1M | — | — |
| FY2021 | $-38.3M | $-38.3M | — | — |
| FY2022 | $-52.8M | $-52.8M | — | — |
| FY2023 | $-53.6M | $-53.6M | — | $3.6M |
| FY2024 | $-57.0M | $-58.0M | $1.0M | — |
| FY2025 | $-44.8M | $-46.3M | $1.5M | — |